This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Walmart opposes dismissal of amended US generic drug pricing claims

( November 21, 2025, 19:49 GMT | Official Statement) -- MLex Summary: Walmart has filed an opposition to dismissal of its amended US generic drug price-fixing claims, arguing that multiple separate motions-to-dismiss from pharmaceutical manufacturers are futile given that a federal court has previously ruled the overarching conspiracy claim is well-pleaded. Instead of challenging the claims on the merits, defendants challenge a handful of Walmart's claims regarding drug-specific conduct. "This Court should deny Defendants’ motions to dismiss. Defendants ask the Court to chip away at the complaint by dismissing individual drug conspiracies, but their arguments go nowhere," Walmart said in its opposition filed to the Eastern District of Pennsylvania. See attached document: ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections